iRadimed Corporation (NASDAQ:IRMD) Receives $120.00 Average PT from Analysts

Shares of iRadimed Corporation (NASDAQ:IRMD) have earned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have covered the stock in the last year is $120.00.

A number of research analysts recently issued reports on IRMD shares. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, August 3rd.

Insider Activity at iRadimed

In related news, CEO Roger E. Susi sold 5,000 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $87.51, for a total transaction of $437,550.00. Following the completion of the sale, the chief executive officer directly owned 2,175,000 shares in the company, valued at $190,334,250. This represents a 0.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 10,000 shares of company stock worth $883,750. 34.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IRMD. Tudor Investment Corp ET AL bought a new position in iRadimed in the third quarter valued at about $666,000. Baader Bank Aktiengesellschaft bought a new stake in shares of iRadimed during the fourth quarter worth about $595,000. Bridge City Capital LLC increased its stake in shares of iRadimed by 19.4% in the fourth quarter. Bridge City Capital LLC now owns 70,854 shares of the medical equipment provider’s stock valued at $6,893,000 after buying an additional 11,509 shares during the period. RFG Advisory LLC acquired a new position in shares of iRadimed in the fourth quarter valued at approximately $1,594,000. Finally, Dimensional Fund Advisors LP raised its holdings in iRadimed by 4.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 226,146 shares of the medical equipment provider’s stock valued at $21,768,000 after buying an additional 9,017 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

iRadimed Stock Down 1.7%

Shares of iRadimed stock opened at $87.40 on Monday. The company has a market capitalization of $1.12 billion, a price-to-earnings ratio of 48.83 and a beta of 0.90. iRadimed has a 12-month low of $67.84 and a 12-month high of $107.90. The firm’s 50-day moving average price is $94.42 and its two-hundred day moving average price is $95.04.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The company had revenue of $20.47 million during the quarter, compared to analysts’ expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, sell-side analysts expect that iRadimed will post 1.98 earnings per share for the current year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed’s payout ratio is 44.69%.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.